Openbookopenbook
Equity
HIMS
+0.0 · +0.00%
USD · NYSE

Hims Hers Health Inc(HIMS) Stock Analysis | Healthcare

USD --+0.00%
Reward61Moderate
Risk72High
75%Data
Thin -6% profit margin · Revenue growing 38% YoY
Profitless Growth
Market Cap:7.88Bn
ⓘ
Reward Rating
61
Moderate
Reward Assessment
75% data coverage
Top 50% of stocksView factors
ⓘ
Risk Rating
72
High
Risk Assessment
4 metrics flaggedView details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on HIMS to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
New listing — limited trading history
Fundamental and analyst data are available for HIMS, but momentum and volatility metrics will develop as more trading history accumulates (0 trading sessions so far).
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $30.85.

What is Hims Hers Health Inc?

operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, and internationally.

HIMS · Verdict

Solid reward · high risk

HIMS stands out on growth and cash flow, but watch the volatility signal.

Based on 88% data coverage

HIMS · Verdict

What’s working & what to watch

Strengths 2

  • Growth92/100

    Revenue +64.5% CAGR

  • Cash flow67/100

    3% free-cash-flow margin

Watchouts 3

  • Volatility5/100

    Weak vs peers

  • Valuation9/100

    P/E 58.8× · PEG 2.15

  • Balance sheet45/100

    Net debt/EBITDA 5.0×

Model-based scoring. For information only — not financial advice.

What is Hims Hers Health Inc?

operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. The company is listed on the NYSE in USA, operating in the Healthcare sector, with a market capitalisation of 7.88B.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Adequate profitability with some margin variability in recent periods.
Risk
Moderate volatility with meaningful macro and earnings sensitivity.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (61)

The scoring profile indicates moderate reward potential, with growth and profitability as the leading contributors. Risk indicators are high — this profile reflects meaningful downside exposure.

For informational purposes only. Not financial advice.

Similar stocks to compare

A short list of Drug Manufacturers - Specialty & Generic names that are close enough in size to make side-by-side comparison useful.

SMDPYMid Cap / 7.9B market cap
Sumitomo Pharma Co. Ltd
Compare
RGEDFMid Cap / 7.9B market cap
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
Compare
ALKSMid Cap / 8.1B market cap
Alkermes Plc
Compare
Company Information
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Market Cap7.88B
P/E RatioN/A
Dividend YieldN/A
Beta2.415
Insider Activity
12M windowBearish
Shares soldShares bought
0-3months
0
0
3-6months
9204,857 shares
$5.3M
0
6-9months
882,963 shares
$2.9M
0
9-12months
246,374 shares
$1.7M
0
1 disclosure without share count
openbook

Stock research for UK and US investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.